Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial - Concepedia

Concepedia

Publication | Closed Access

Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial

107

Citations

22

References

2013

Year

J. Hensen, Campbell P. Howard, Verena Walter, Tom Thurén

Diabetes & Metabolism

Diabetes ManagementHealth PolicyDiabetesType 2Blood Glucose MonitoringSecondary EndpointsDiabetes Mellitus

References

	Year	Citations

Page 1